國立虎尾科技大學 |

Immunotherapy for head and neck cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Immunotherapy for head and neck cancer/ edited by Anthony T. C. Chan, Brigette B.Y. Ma.
other author:	Chan, Anthony T. C.
Published:	Cham :Springer Nature Switzerland : : 2023.,
Description:	viii, 147 p. :ill. (some col.), digital ; : 24 cm.;
Contained By:	Springer Nature eBook
Subject:	Head - Cancer -
Online resource:	https://doi.org/10.1007/978-3-031-29223-1
ISBN:	9783031292231

Immunotherapy for head and neck cancer
Immunotherapy for head and neck cancer[electronic resource] /edited by Anthony T. C. Chan, Brigette B.Y. Ma. - Cham :Springer Nature Switzerland :2023. - viii, 147 p. :ill. (some col.), digital ;24 cm. - Cancer Immunotherapy,v. 12662-8392 ;. - Cancer Immunotherapy ;v. 1..

Immunological Landscape of Head and Neck Cancer: Mechanisms of Immune Escape and the Tumor Microenvironment -- Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer -- Immunotherapy in Locally Advanced Nasopharyngeal Carcinoma -- Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma -- Beyond PD-1/PD-L1 Immune Checkpoint Inhibitors: Other Targets and Approaches for Head and Neck Cancer -- Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment of Head and Neck Cancer -- Clinical Application of Immunotherapy in the Perioperative Management of Head and Neck Cancer -- The Role of Immune Checkpoint Inhibitors in the Treatment of Less Common Head and Neck Cancers -- Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer.

This book is a comprehensive summary of the literature on the scientific rationale and clinical development of immunotherapy for head and neck cancers. Head and neck cancer is a biologically diverse group of cancers that bear a common hallmark - evasion of host immune surveillance through innate or acquired mechanisms. The etiological association between the Human Papilloma virus (HPV) and some squamous head and neck cancers, the Epstein-Barr virus (EBV) and nasopharyngeal cancer has provided further impetus for evaluating immunotherapy in this group of cancers. The successful development of anti-programmed cell death protein-1 (PD-1)/ ligand (PD-L1) and CTLA-4 antibodies in solid tumours has gradually brought immunotherapy into mainstream oncological practice in recent years. Besides immune-checkpoint proteins inhibitors, other forms of immunotherapy such as vaccines, EBV or HPV-targeting therapies and cellular therapies are actively being investigated in clinical trials, either alone or in combination with other conventional treatments such as radiotherapy, chemotherapy and surgery. In clinical setting, the practicing oncologist need to be familiar with some unusual patterns of immunological response such as pseudo-progression and hyper-progression in patients with head and neck cancers who are undergoing treatment with immune-checkpoint inhibitors. Furthermore, the unique side effects of immune-checkpoint inhibitors such as autoimmune toxicities need to be recognized early and treated expediently. The development of biomarkers in predicting response to immune-checkpoint inhibitors has played pivotal roles in selecting patients for immunotherapy in practice or as an enrichment strategy in clinical trials. There are now emerging data on the clinical utility of biomarkers such as PD-L1 expression (Combined Positive Score), gene signatures and tumor mutational burden. This book is an invaluable companion to all those who are involved in research and clinical management of patients with head and neck cancers from any endemic regions.

ISBN: 9783031292231

Standard No.: 10.1007/978-3-031-29223-1doiSubjects--Topical Terms:

1431821
Head
--Cancer

LC Class. No.: RC280.H4 / I56 2023

Dewey Class. No.: 616.9949106

Immunotherapy for head and neck cancer
LDR:03968nam a2200337 a 4500 001 1117873
003 DE-He213
005 20231014204819.0
006 m d
007 cr nn 008maaau
008 240126s2023 sz s 0 eng d
020 $a 9783031292231 $q (electronic bk.)
020 $a 9783031292255 $q (paper)
024 7 $a 10.1007/978-3-031-29223-1 $2 doi
035 $a 978-3-031-29223-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.H4 $b I56 2023
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.9949106 $2 23
090 $a RC280.H4 $b I33 2023
245 0 0 $a Immunotherapy for head and neck cancer $h [electronic resource] / $c edited by Anthony T. C. Chan, Brigette B.Y. Ma.
260 $a Cham : $c 2023. $b Springer Nature Switzerland : $b Imprint: Springer,
300 $a viii, 147 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Cancer Immunotherapy, $x 2662-8392 ; $v v. 1
505 0 $a Immunological Landscape of Head and Neck Cancer: Mechanisms of Immune Escape and the Tumor Microenvironment -- Drug Targets and Strategies in the Clinical Development of Immunotherapy for Head and Neck Cancer -- Immunotherapy in Locally Advanced Nasopharyngeal Carcinoma -- Immunotherapy in Recurrent and Metastatic Nasopharyngeal Carcinoma -- Beyond PD-1/PD-L1 Immune Checkpoint Inhibitors: Other Targets and Approaches for Head and Neck Cancer -- Translational and Clinical Approach to Combining Immunotherapy with Radiotherapy in the Treatment of Head and Neck Cancer -- Clinical Application of Immunotherapy in the Perioperative Management of Head and Neck Cancer -- The Role of Immune Checkpoint Inhibitors in the Treatment of Less Common Head and Neck Cancers -- Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer.
520 $a This book is a comprehensive summary of the literature on the scientific rationale and clinical development of immunotherapy for head and neck cancers. Head and neck cancer is a biologically diverse group of cancers that bear a common hallmark - evasion of host immune surveillance through innate or acquired mechanisms. The etiological association between the Human Papilloma virus (HPV) and some squamous head and neck cancers, the Epstein-Barr virus (EBV) and nasopharyngeal cancer has provided further impetus for evaluating immunotherapy in this group of cancers. The successful development of anti-programmed cell death protein-1 (PD-1)/ ligand (PD-L1) and CTLA-4 antibodies in solid tumours has gradually brought immunotherapy into mainstream oncological practice in recent years. Besides immune-checkpoint proteins inhibitors, other forms of immunotherapy such as vaccines, EBV or HPV-targeting therapies and cellular therapies are actively being investigated in clinical trials, either alone or in combination with other conventional treatments such as radiotherapy, chemotherapy and surgery. In clinical setting, the practicing oncologist need to be familiar with some unusual patterns of immunological response such as pseudo-progression and hyper-progression in patients with head and neck cancers who are undergoing treatment with immune-checkpoint inhibitors. Furthermore, the unique side effects of immune-checkpoint inhibitors such as autoimmune toxicities need to be recognized early and treated expediently. The development of biomarkers in predicting response to immune-checkpoint inhibitors has played pivotal roles in selecting patients for immunotherapy in practice or as an enrichment strategy in clinical trials. There are now emerging data on the clinical utility of biomarkers such as PD-L1 expression (Combined Positive Score), gene signatures and tumor mutational burden. This book is an invaluable companion to all those who are involved in research and clinical management of patients with head and neck cancers from any endemic regions.
650 0 $a Head $x Cancer $x Immunotherapy. $3 1431821
650 0 $a Neck $x Cancer $x Immunotherapy. $3 1431822
650 1 4 $a Immunotherapy. $3 592896
650 2 4 $a Oncology. $3 593951
650 2 4 $a Radiation Oncology. $3 1388865
650 2 4 $a Surgery. $3 644132
650 2 4 $a Otorhinolaryngology. $3 668435
700 1 $a Chan, Anthony T. C. $3 1431818
700 1 $a Ma, Brigette B. Y. $3 1431819
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
830 0 $a Cancer Immunotherapy ; $v v. 1. $3 1431820
856 4 0 $u https://doi.org/10.1007/978-3-031-29223-1
950 $a Medicine (SpringerNature-11650)